体内研究 (In Vivo) |
ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠埋珠试验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。 ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠高架十字迷宫实验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。 ADX71441 (0.3-3 mg/kg; p.o.; 单次给药) 在大鼠高架十字迷宫实验中产生剂量依赖性的类抗焦虑作用,最低有效剂量为 3 mg/kg。 ADX71441 (30 mg/kg; p.o.; 单次给药) 在大鼠高架十字迷宫实验中,给药后 24 小时仍具有类抗焦虑功效。 ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在小鼠醋酸扭体试验中产生剂量依赖性和时间依赖性的镇痛作用。 ADX71441 (10 mg/kg; p.o.; 单次给药) 在大鼠转棒试验中产生肌肉松弛作用。 ADX71441 (10 mg/kg; p.o.; 单次给药) 可降低经急性灌胃给药小鼠的自主活动能力。 ADX71441 (3-30 mg/kg; p.o.; 单次给药) 经急性口服给药后,可使大鼠的自发活动呈剂量依赖性降低,其最低有效剂量为 3 mg/kg。 ADX71441 (30 mg/kg; p.o.; 每日一次一共 7 天) 经亚慢性口服给药后,会使其在小鼠中产生的运动抑制效应出现耐受。 ADX71441 (3-30 mg/kg; p.o.; 单次给药) 可通过激活 GABAB 受体在小鼠中产生剂量依赖性的降温作用,其最低有效剂量为 10 mg/kg。 ADX71441 (3-30 mg/kg; p.o.; 单次给药) 在大鼠中产生剂量依赖性的短暂降温作用,最低有效剂量为 3 mg/kg。 ADX71441 (1-10 mg/kg; p.o.; 单次给药) 剂量依赖性地减少 Furosemide (MS-I80061) 诱导的过度活跃膀胱 (OAB) 小鼠的尿频事件总数、总尿量、平均尿量,并增加首次排尿潜伏期。 ADX71441 (1-3 mg/kg; i.v.; 单次给药) 可快速改善 Acetic acid (MS-H89626) 诱导的豚鼠 OAB 的尿动力学参数。 ADX71441 (1-30 mg/kg; i.p.; 单次给药) 可剂量依赖性地使非成瘾雄性 Wistar 大鼠的 20% 酒精自主摄取量降低。 ADX71441 (1-3 mg/kg; i.p.; 单次给药) 在酒精依赖的雄性 Wistar 大鼠中表现出更强的减少酒精自服行为的效力。 ADX71441 (3-10 mg/kg; i.p.; 单次给药) 可强效阻断经训练能够自主摄酒的雄性 Wistar 大鼠中由线索诱导和应激诱导的类复吸饮酒行为。 ADX71441 (3 mg/kg; i.p.; 单次给药) 可减轻雄性 Wistar 大鼠中与应激诱导的复吸样觅酒行为相关的脑区网络 (伏隔核壳部、中央杏仁核、中缝背核和内侧前额叶皮层) 内的应激诱导神经元激活。 ADX71441 (0.3-15 mg/kg; p.o.; 每日一次共 7 天) 在 Sodium iodoacetate (MS-X68601) 诱导的大鼠骨关节炎模型中表现出剂量依赖性的抗痛觉过敏功效。 ADX71441 (1-10 mg/kg; p.o.; 单次给药) 在大鼠上具有肌肉松弛作用。
| Animal Model: |
C57Bl6/J (male, adult, 24-30g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose; 60 minutes pre-test |
| Result: |
Showed no effect at 1 mg/kg. Produced a ~55% reduction in buried marbles at 3 mg/kg. Fully suppressed burying behavior at 10 mg/kg. Reached mean plasma concentrations of 144 ng/mL (1 mg/kg), 341 ng/mL (3 mg/kg), and 629 ng/mL (10 mg/kg) at end of experiment.\nShowed no effect at 1 mg/kg. Produced ~2-fold increases in open arm entries at 3 mg/kg and 10 mg/kg. Produced a ~2-fold increase in time spent on open arms at 3 mg/kg, and an almost 3-fold increase at 10 mg/kg. Showed no effect on closed arm exploration. Reached mean plasma concentrations of 168 ng/mL (1 mg/kg), 399 ng/mL (3 mg/kg), and 688 ng/mL (10 mg/kg) at end of experiment. |
| Animal Model: |
Sprague-Dawley (male, adult, 250-350g) |
| Dosage: |
0.3 mg/kg; 1 mg/kg; 3 mg/kg |
| Administration: |
p.o.; single dose; 60 minutes pre-test |
| Result: |
Showed no effect at 0.3 mg/kg and 1 mg/kg. Produced more than 3-fold increases in open arm entries and more than 4-fold increases in time spent on open arms at 3 mg/kg. Showed no effect on closed arm exploration. Reached mean plasma concentrations of 46 ng/mL (1 mg/kg), 171 ng/mL (3 mg/kg) at end of experiment. |
| Animal Model: |
Sprague-Dawley (male, adult, 250-350g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; 24 hours pre-test |
| Result: |
Showed no effect at 1 mg/kg and 3 mg/kg. Showed a trend toward reduced open arm entries at 10 mg/kg. Produced almost 4-fold increases in open arm entries and almost 4-fold increases in time spent on open arms at 30 mg/kg. Showed no effect on closed arm entries. Reached mean brain concentrations of 40 ng/g (1 mg/kg), 107 ng/g (3 mg/kg), 427 ng/g (10 mg/kg), and 1014 ng/g (30 mg/kg); mean plasma concentrations of 11 ng/mL (1 mg/kg), 52 ng/mL (3 mg/kg), 321 ng/mL (10 mg/kg), and 898 ng/mL (30 mg/kg) at end of experiment. |
| Animal Model: |
C57Bl6/J (male, adult, 24-30g; separate cohort from SLAC, Shanghai, China) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose; 70 minutes pre-test (dose-response); 1, 2, 4 hours pre-test (time-course) |
| Result: |
Showed no effect at 1 mg/kg in dose-response study. Produced a 55% reduction in writhes at 3 mg/kg, and an almost 90% reduction at 10 mg/kg in dose-response study. Produced an ~80% reduction in writhes at 1 hour post-treatment, ~60% reduction at 2 hours, and ~25% reduction (trend) at 4 hours with 10 mg/kg in time-course study. Reached mean plasma concentrations of 562 ng/mL (1 hour), 566 ng/mL (2 hours), and 343 ng/mL (4 hours) in time-course study. |
| Animal Model: |
Sprague-Dawley (male, adult, 250-350g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose; measured at 60, 120, 180 minutes post-treatment |
| Result: |
Showed no effect at 1 mg/kg and 3 mg/kg across all time points. Reduced time on rotarod by approximately 50% at all time points at 10 mg/kg. |
| Animal Model: |
C57Bl6/J (male, adult, 24-30g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose; 60 minutes pre-test; monitored for 60 minutes |
| Result: |
Showed no effect at 1 mg/kg and 3 mg/kg. Produced a ~40% reduction in total distance travelled at 10 mg/kg. |
| Animal Model: |
Sprague-Dawley (male, adult, 250-350g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; 60 minutes pre-test; monitored for 60 minutes |
| Result: |
Showed no effect at 1 mg/kg. Produced an ~50% reduction in total distance travelled at 3 mg/kg, ~85% reduction at 10 mg/kg, and almost 100% reduction at 30 mg/kg. |
| Animal Model: |
C57Bl6/J (male, adult, 24-30g; cohort from Charles River Laboratories, Wilmington, MA) |
| Dosage: |
10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; once daily for 7 days plus acute dose on day 8; 60 minutes pre-test on day 8; monitored for 60 minutes |
| Result: |
Showed no reduction in locomotor activity (total distance travelled or rearing) with acute 30 mg/kg dose in mice with sub-chronic 30 mg/kg treatment history. Produced an ~50% reduction in total distance travelled and ~90% reduction in rears with acute 30 mg/kg dose, and no effect with acute 10 mg/kg dose in vehicle-treated mice. |
| Animal Model: |
C57Bl6/J (male, adult, 24-30g; cohort from Janvier, Le Genest Saint Isle, France) |
| Dosage: |
3 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; measured at 1, 2, 4 hours post-treatment (acute); p.o. 30 mg/kg plus oral CGP63360 30 minutes later (target engagement) |
| Result: |
Showed no effect at 3 mg/kg in acute dose-response study. Produced a 1.5°C reduction at 1 and 2 hours at 10 mg/kg, and a ~3°C reduction at 1 and 2 hours plus 1.77°C reduction at 4 hours at 30 mg/kg in acute dose-response study. Had hypothermic effects dose-dependently reversed by CGP63360 in target engagement study; 3 mg/kg CGP63360 returned body temperature to normal at 2 and 4 hours post-ADX71441 treatment. |
| Animal Model: |
Sprague-Dawley (male, adult, 250-350g) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
p.o.; single dose; measured at 1, 2, 4, 20 hours post-treatment |
| Result: |
Showed no effect at 1 mg/kg. Produced 0.5-1.2°C reductions at 1, 2, and 4 hours at 3 mg/kg and 10 mg/kg. Produced 1.4-1.8°C reductions at 1, 2, and 4 hours at 30 mg/kg. Showed no effect at 20 hours post-treatment across all doses. |
| Animal Model: |
C57Bl6/J (adult male, 24-30 g, overhydrated with water and challenged with furosemide to induce bladder overactivity) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg |
| Administration: |
p.o.; single dose |
| Result: |
Produced a 70% reduction in total urinary events, a more than threefold increase in latency to the first urinary event, a 55% reduction in total urinary volume, and an approximately 65% reduction in average urinary volume compared to vehicle-treated mice at 10 mg/kg. Normalized urinary parameters to levels not significantly different from intact untreated controls for number of urinary events, latency to first event, and average urinary volume at 3 mg/kg and 10 mg/kg. Normalized total urinary volume to levels not significantly different from intact untreated controls at 10 mg/kg. Achieved plasma concentrations of 101 ng/mL (1 mg/kg), 208 ng/mL (3 mg/kg), and 652 ng/mL (10 mg/kg), corresponding to unbound plasma concentration/EC50 ratios of 0.36, 0.74, and 2.31 respectively. |
| Animal Model: |
Dunkin Hartley (adult female, 290-370 g, OAB induced by intravesical infusion of 0.2% acetic acid) |
| Dosage: |
1 mg/kg; 3 mg/kg |
| Administration: |
i.v.; single bolus dose |
| Result: |
Significantly increased intercontraction interval and bladder capacity at 1 mg/kg and 3 mg/kg 0-15 minutes post-administration. Significantly reduced micturition frequency compared to vehicle at 1 mg/kg 0-15 minutes post-administration. Significantly increased threshold pressure compared to vehicle at 3 mg/kg 0-15 minutes post-administration. Completely inhibited the micturition reflex, inducing overflow incontinence, in 5 out of 10 animals at 3 mg/kg. Achieved plasma concentrations of 67 ng/mL (1 mg/kg) and 195 ng/mL (3 mg/kg), corresponding to unbound plasma concentration/EC50 ratios of 0.3 and 0.9 respectively. |
| Animal Model: |
Wistar rats (adult male, 200-225g at study initiation, trained to self-administer 20% alcohol on FR2 schedule) |
| Dosage: |
1 mg/kg; 3 mg/kg; 10 mg/kg; 30 mg/kg |
| Administration: |
i.p. |
| Result: |
Showed no significant reduction in alcohol reinforcers earned or active lever presses, and no effect on locomotor activity at 1 mg/kg. Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, no alteration to locomotor activity, and potent reduction in alcohol breakpoints at 3 mg/kg. Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, no alteration to locomotor activity, and potent reduction in alcohol breakpoints at 10 mg/kg. Produced statistically significant reduction in alcohol reinforcers earned and active lever presses, and significant reduction in locomotor activity at 30 mg/kg. |
| Animal Model: |
Wistar rats (adult male, 200-225g at study initiation; alcohol-dependent via chronic intermittent 14-hour daily alcohol vapor exposure for 8 weeks; non-dependent control exposed to normal air) |
| Dosage: |
1 mg/kg; 3 mg/kg |
| Administration: |
i.p. |
| Result: |
Significantly decreased alcohol reinforcers earned and active lever presses in alcohol-dependent rats but had no significant effect in non-dependent rats at 1 mg/kg. Significantly decreased alcohol reinforcers earned and active lever presses in both alcohol-dependent and non-dependent rats at 3 mg/kg. |
...(内容过长已截断) |